$DHR (+0,89 %) | Danaher Q3'24 Earnings Highlights:

🔹 Adj EPS: $1.71 (Est. $1.57) 🟢 

🔹 Revenue: $5.80B (Est. $5.59B) 🟢; UP +3% YoY 

🔹 Net Cash Provided by Operating Activities: $1.5B (Est. $1.27B) 🟢 

🔹 Non-GAAP Free Cash Flow: $1.2B

🔹 Operating Profit: $958M 

Guidance:

🔹 For Q4'24, anticipates non-GAAP core revenue to decline low-single digits YoY 

🔹 For FY'24, continues to expect non-GAAP core revenue to be down low-single digits YoY

CEO Rainer M. Blair's Commentary: 

🔸 "Our team delivered strong third quarter results, including better-than-expected revenue growth. We were especially pleased with the continued positive momentum in our bioprocessing business and believe Cepheid gained market share in molecular testing again this quarter."

🔸 "Looking ahead, we believe the combination of our leading portfolio and DBS-driven execution differentiates Danaher and provides a strong foundation for sustainable long-term value creation while helping to meaningfully improve human health."